Autres langues Amgen Inc.

Actions

AMGN

US0311621009

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 21:00:00 13/03/2026			Varia. 5j.	Varia. 1 janv.
366,21 ^USD	-0,43 %		-0,90 %	+11,88 %

00:49	GSK et Amgen vont ajouter des médicaments à TrumpRx, selon Fox Business	RE
12/03	GRAIL, Inc. annonce des changements au sein de son conseil d'administration	CI

Autres langues

00:49	GSK and Amgen to add medicines to TrumpRx, Fox Business reports
12/03	GRAIL, Inc. Announces Board Changes
12/03	GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026
12/03	Grail CEO Bob Ragusa to retire, Josh Ofman named successor
10/03	Equinix, Inc. Appoints Olivier Leonetti as Chief Financial Officer, Effective March 16, 2026
09/03	Global drugmakers rush to boost US presence as tariff threat looms
09/03	LB Pharmaceuticals Inc Appoints Robert Lenz, M.D., Ph.D. to Board of Directors
05/03	AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
05/03	Arcutis Biotherapeutics, Inc. Announces Promotion of Mas Matsuda to Executive Vice President, Chief Legal Officer, and Corporate Secretary
05/03	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset
04/03	Amgen Keeps Quarterly Dividend at $2.52 a Share, Payable June 5 to Holders of Record May 15
04/03	Amgen announces 2026 second quarter dividend
04/03	AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
04/03	Amgen Announces 2026 Second Quarter Dividend, Payable on June 5, 2026
04/03	Tivic Health Systems, Inc. Announces CEO Changes
04/03	Tivic Health Systems, Inc. Announces Board Changes
04/03	NervGen Pharma Corp. Announces Executive Changes
03/03	PRF Technologies Ltd. Announces CEO Changes, Effective February 25, 2026
03/03	Absci Corporation Announces Executive Changes
03/03	Kyowa Kirin stops development of skin condition treatment
03/03	Kyowa Kirin announces discontinuation of Rocatinlimab clinical trials
03/03	Kyowa Kirin Co., Ltd. Discontinues All Ongoing Clinical Trials for Rocatinlimab
01/03	Fujian Haixi Pharmaceuticals Co., Ltd. Appoints Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, Effective March 1, 2026
27/02	Generate Biomedicines shares fall in weak Nasdaq debut for drug developer
27/02	Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut